Setting priorities for comparative effectiveness research in inflammatory bowel disease: Results of an international provider survey, expert rand panel, and patient focus groups
Adam S. Cheifetz(Beth Israel Deaconess Medical Center), Corey A. Siegel(Dartmouth–Hitchcock Medical Center), Fernando Velayos(Kaiser Permanente San Francisco Medical Center), Shane Devlin, Gilaad G. Kaplan(University of Calgary), Peter M. Irving(Guy's and St Thomas' NHS Foundation Trust), Brennan Spiegel(Cedars-Sinai Medical Center), Leonard Baidoo(University of Pittsburgh Medical Center), Gil Melmed, Brian Bressler(University of British Columbia), Jennifer Jones(Dalhousie University), Miles Sparrow(Alfred Health), Patricia Kozuch(Thomas Jefferson University), Laura H. Raffals, Jennifer Talley(Digestive Care (United States))
Cited by 16
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
ACG Clinical Guideline: Ulcerative Colitis in Adults
|The American Journal of Gastroenterology|2019|1.6k